{"commentary":{"count":109,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":51,"podcast":42,"x_thread":16},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03839823\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"RIGHT Choice","nct_id":"NCT03839823","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=right-choice-nct03839823. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"RIGHT Choice","arms":[{"description":"Combination of non-steroidal aromatase inhibitor: NSAI (letrozole or anastrozole) + goserelin + ribociclib.\n\n1. Ribociclib (600 mg) was dosed orally for the first 21 days out of a 28-day cycle.\n2. Letrozole (2.5 mg) or anastrozole (1 mg) were dosed orally daily (28 days out of the 28-day cycle).\n3. Goserelin (3.6 mg) was continuously released via a subcutaneous implant injected on Day 1 of each 28-day cycle (regardless of ribociclib treatment cycle) with an administration window of + 3 days.","label":"Ribociclib 600 mg","type":"EXPERIMENTAL"},{"description":"Combination chemotherapies of docetaxel/capecitabine, paclitaxel/gemcitabine or capecitabine/vinorelbine were administered to patients enrolled in the control group. The chemotherapy regimen was decided by the treating physician.","label":"Combination Chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2023-05-10","type":"ACTUAL"},"conditions":["Breast Cancer"],"enrollment":{"count":222,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Docetaxel / Capecitabine","type":"COMBINATION_PRODUCT"},{"name":"Capecitabine / Vinorelbine","type":"COMBINATION_PRODUCT"},{"name":"Paclitaxel / Gemcitabine","type":"COMBINATION_PRODUCT"},{"name":"Ribociclib","type":"DRUG"},{"name":"Letrozole OR Anastrozole","type":"DRUG"},{"name":"Goserelin","type":"DRUG"}],"last_update":"2024-10-09","lead_sponsor":"Novartis Pharmaceuticals","official_title":"A Phase II Randomized Study of the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Physician Choice Chemotherapy in Premenopausal or Perimenopausal Patients With Hormone Receptor-positive/ HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2022-04-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival","timeFrame":"Up to approximately 34 months"}],"references":[{"citation":"Lu YS, Mahidin EIBM, Azim H, Eralp Y, Yap YS, Im SA, Rihani J, Gokmen E, El Bastawisy A, Karadurmus N, Lim YN, Lim CS, Duc LT, Chung WP, Babu KG, Penkov K, Bowles J, Alfaro TD, Wu J, Gao M, Slimane K, El Saghir NS. Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. J Clin Oncol. 2024 Aug 10;42(23):2812-2821. doi: 10.1200/JCO.24.00144. Epub 2024 May 21.","pmid":"38771995","type":"DERIVED"}],"start_date":{"date":"2019-02-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer","url":"https://clinicaltrials.gov/study/NCT03839823"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/right-choice-nct03839823"}